The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
Interim but promising updates on first-in-human phase I/II clinical trial for GTB-3550 TriKE™ to treat R/R MDS/AML patients
GTB-3550 tri-specific killer cell engager (TriKE™) is a tri-specific scFv recombinant fusion protein conjugate, containing variable regions of the H and L chains of the anti-CD16 and anti-CD33 antibodies along with modified IL-15. The drug is used as a monotherapy treatment and acts on CD33+ leukemias such as acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS) by activating the apoptotic action of natural killer (NK) cells on malignant cells, which contributes to tumor-induced immunosuppression.
Recently, an update on the first-in-human phase I/II clinical trial (NCT03214666) for GTB-3550 TriKE™ to treat relapsed/refractory (R/R) MDS/AML patients was published.1
Major outcomes obtained from treating the first nine patients in the trial are as follows:
- Three out of the last five patients treated responded to the therapeutic dose range (25 mcg/kg/day to 100 mcg/kg/day).
- Reduction (63.7%) in the bone marrow blast level was observed.
- Restoration of endogenous NK cell function, proliferation, and immune surveillance was also detected.
- None of the patients showed cytokine release syndrome.
GTB-3550 TriKE™ would be a cost-effective option as no preconditioning (progenitor-derived or autologous/allogenic cell therapy) of patients is required. Also, it was observed to be well tolerated with reduced toxicity and, therefore, offers the advantage to be used at an early stage of the disease.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content